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Pulmonary arterial hypertension (PAH) is a rare and devastating disease which is characterized by worsening dyspnea and exercise tolerance. These patients are often found to have concomitant, depression,
anxiety and impaired health-related quality of life (HRQOL). The interrelationship of dyspnea, depression and HRQOL in these patients is not
well studied. Retrospective analysis was performed on 46 PAH patients
(mean age 51.73). Patients completed Medical Outcomes Study Short Form 36 V2 (SF-36) to measure HRQOL, Modified Medical Research
Council (mMRC) Dyspnea Scale and Zung Depression Scale (ZDS).
Physical Health Composite Scores (PCS) and Mental Health Composite
Scores (MCS) were derived from SF-36. Spearman’s correlation was
computed to determine degree of correlation between pairs of scales.
46 patients (12 males, 34 females; median age 51.4 yr) with confirmed
PAH were considered for the study of which 36 patients (9 males, 27 fe-

males, median age 50.1 yr), were eligible for further analysis. MMRC
Dyspnea Scale Score was 1.0 (Q1 to Q3:1.0 to 2.0). Median MCS was
52.1 (Q1 to Q3:41.7 to 57.1) and PCS was 37.9 (Q1 to Q3: 30.7 to 49.6).
There was a significant negative correlation between dyspnea and PCS
(r = -0.660, P< 0.0001) and MCS (r = -0.342, P< 0.0411). The ZDS was available for 17 of these patients; their median score was 42.0 (Q1 to Q3: 33.0 to
46.0). There was a significant correlation between the ZDS and PCS (r
= -0.578, P< 0.0150,) MCS (r = -0.752, P< 0.0005). Patients with PAH suffer
from diminished HRQOL correlating with their dyspnea and underlying
depression.
Keywords: Pulmonary arterial hypertension, Dyspnea, Depression,
Health related quality of life, Patient reported outcomes, Pulmonary hypertension

INTRODUCTION

infection, congenital heart disease or heritable in nature. Symptomatically PAH patients are characterized by increasing shortness of breath and worsening exercise tolerance.
Due to the progressive nature of this condition and its debilitations, patients with PAH have been often found to have concomitant, depression, anxiety and severely impaired health-related
quality of life (HRQOL) (Löwe et al., 2004; Taichman et al.,
2005; Verma et al., 2014). It is also known that dyspnea, a major
component of this disease, is independently related to depressive
symptoms (Kellner et al., 1992). The effects and relationship of
dyspnea, depression and HRQOL in these patients is not well
studied but it is very important, as it may shine a light on psychosomatic domains of this disease which sets the basis of this study.
We decided to study the relationship of patient self report dys-

Pulmonary hypertension (PHTN) is a rare and devastating disease characterized by progressive increases in pulmonary arterial
pressure and pulmonary vascular resistance which eventually leads
to right ventricular failure and death (Farber and Loscalzo, 2004).
It may due to various etiologies such as left heart disease, parenchymal lung disease leading to hypoxia, chronic thromboembolic
disease, hematologic disorders or it may be idiopathic in nature.
The World Health Organization (WHO) has created a classification system for pulmonary hypertension based on common clinical features (Simonneau et al., 2013). Pulmonary arterial hypertension (PAH), considered WHO Group I PHTN, is often considered idiopathic or may due to connective tissue disease, HIV
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pnea, depression and HRQOL in patients with WHO Group I
PAH.

MATERIALS AND METHODS
Patients
Retrospective chart analysis was performed on 46 patients with
a diagnosis of pulmonary hypertension at the North Shore – Long
Island Jewish Health System who were being considered for pulmonary rehabilitation. Pulmonary hypertension was defined in
accordance to the ACCF/AHA guidelines (McLaughlin et al.,
2009). Pulmonary arterial hypertension (PAH) is defined hemodynamically as a mean pulmonary artery pressure (mPAP) greater
than or equal 25 mmHg and a pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg which must be confirmed by right heart catheterization (RHC) (Badesch et al.,
2009). As a part of their pre-pulmonary rehabilitation screening
patients were asked to complete a series of questionnaires including the MMRC Dyspnea Scale, Zung Depression Scale and Medical Outcomes Study SF-36 V2 Health Survey to measure generic
HRQOL. Physical component scores (PCS) and mental component scores (MCS) were derived from SF36V2. Patients who were
found to have WHO Group I pulmonary arterial hypertension
and had completed the MMRC Dyspnea Scale and the SF-36 were
included in this the study.Data was analyzed using SAS (Cary, NC
USA). The Spearman correlation coefficient was computed to determine the degree of correlation between each pair of scales.
Summary statistics are reported as medians and 25th percentile
(Q1) to 75th percentile (Q3). Institutional Review Board approval
was obtained for this study.
Measuring dyspnea, depression and health related quality
of life
To determine different aspects of psychosomatic health quantitative measurements of dyspnea, depression and health related
quality of life must be determined. Quantification of such data
makes it feasible to determine their correlation, as it may not be
well known. In the setting of pulmonary arterial hypertension, a
chronic debilitating disease, dyspnea, depression, and quality of
life are often intertwined.
Dyspnea
As dyspnea is one of the most common symptoms across cardiovascular and pulmonary medicine, defining its severity is important.Many scales have been identified to measure dyspnea (Cri-
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safulli and Clini, 2010) but the Modified Medical Research Council Dyspnoea Scale (MMRC Dyspnoea Scale) has already previously been used to categorize disability in COPD (Cazzola et al.,
2008). As this is a patient reported scale, patients are asked about
their perceived breathlessness and responses are then classified according to how they perceive their dyspnea. The MMRC dyspnea
scale is a questionnaire that consists of five statements about perceived breathlessness: grade 0, “I only get breathless with strenuous exercise”; grade 1, “I get short of breath when hurrying on the
level or up a slight hill”; grade 2, “I walk slower than people of
the same age on the level because of breathlessness or have to stop
for breath when walking at my own pace on the level”; grade 3, “I
stop for breath after walking 100 yards or after a few minutes on
the level”; grade 4, “I am too breathless to leave the house” or “I
am breathless when dressing”. The MMRC correlates well with
other measures of dyspnea that have been used in the pulmonary
setting as well (Wilson et al., 1997).
Depression
Depression is a common entity amongst PAH patients (Verma
et al., 2014) and to define its severity is important as its presence
may impact dyspnea and HRQOL. Many depression scales have
been developed to measure depression in a primary care setting
(Williams et al., 2002), however the Zung Depression Scale (ZDS)
has been found to be quick, simple and easy to administer to patients (Shafer, 2006). The ZDS is a self-reporting 20-item instrument used to promptly assess severity of depression in patients,
with half of the items stated negatively and the other half stated
positively (Zung, 1965). Each item score range is from 1 through
4. A total score of 50 and greater indicates some severity of depression. The test is quick, simple and easy to administer to patients. It is primarily used in clinical research to monitor treatment (Zung, 1965).
Health related quality of life (HRQOL)
Health-related quality of life is defined by the Center for Disease Control as an assessment of how an individual’s well-being is
being affected over time by a disease, disability, or disorder. Measurement of HRQOL in the setting of PAH has been documented
(Löwe et al., 2004). To assess HRQOL in our patients the SF-36
Health Survey v2 (Medical Outcomes Trust, Boston, MA, USA)
was used as it is a generic measure of health related quality of life
versus specific for disease, gender, age or treatment group (Ware,
2000). The benefit of using the SF-36 is that it is comprised of
two sub components, a mental component summary (MCS) and a

http://dx.doi.org/10.12965/jer.150230
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physical component summary (PCS). The PCS is comprised of 4
subsets: Physical Functioning, Role-Physical, Bodily Pain and
General health. He MCS is comprised of 4 subsets as well: Vitality, Social Functioning, Role-Emotional and Mental Health. Three
scales, (Physical Functioning, Role-Physical, and Bodily Pain)
correlate most highly with the physical component and contribute most to the scoring of the PCS measure (Tucker et al., 2010).
Table 1. Patient characteristics and study results
Age (yr) n= 36
Sex (male/female)
mMRC Dyspnea Scale Score (n= 36)
SF-36 Health Survey MCS (n= 36)
SF-36 Health Survey PCS (n= 36)
Zung Depression Scale (n= 17)

RESULTS

50.01± 13.48
9 (25.0%) / 27 (75.0%)
1.36± 1.15
48.99± 11.74
39.53± 10.95
40.35± 9.00

PCS

60

Whilst the mental component correlates most highly with the
Mental Health, Role-Emotional, and Social Functioning scales,
which contribute most to the scoring of the MCS measure (Tucker
et al., 2010). Normal score for the SF-36 are based on a 0-100
scale with norm-based scoring of the 8 subscales with 50 being
the mean. Expected scores for PCS are 20-58 and 17-62 for MCS
with lower score correlating with reduced physical and mental
quality of life (Ware, 2000).

46 patients (12 males, 34 females; median age 51.4 yr) with confirmed PAH (WHO Group I PHTN) on review of right heart
catheterization data were considered for the study. Ten of these patients were missing data on either the MMRC Dyspnea Scale, or
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Table 2. Summary of correlation between dyspnea, depression and HRQOL scale				

mMRC Dyspnea
Scale Score (n= 36)
SF-36 Health
Survey MCS (n= 36)
SF-36 Health
Survey PCS (n= 36)
Zung Depression
Scale (n= 17)

mMRC Dyspnea
Scale Score (n= 36)

SF-36 Health
Survey MCS (n= 36)

SF-36 Health
Survey PCS (n= 36)

Zung Depression
Scale (n= 17)

-

r= -0.342
P< 0.0411
-

r= -0.660
P< 0.0001
NS

NS

-

r= -0.752
P< 0.0005

r= -0.578
P< 0.0150

r= 0.620
P< 0.0079
r= -0.752
P< 0.0005
r= -0.578
P< 0.0150
-

r= -0.342
P< 0.0411
r= -0.660
P< 0.0001
r= 0.620
P< 0.0079

NS, Not statistically significant.				

the SF-36 questionnaire, or both, and so were excluded from further analysis. Thirty-six patients (9 males, 27 females, median age
50.1 yr), were eligible for further analysis (Table 1). The self reported median dyspnea in this PAH Group was 1.0 (Q1 to
Q3:1.0 to 2.0) according to the mMRC Dyspnea Scale Score. The
median mental component score (MCS) was 52.1 (Q1 to Q3:41.7
to 57.1) and physical component scores (PCS) was 37.9 (Q1 to
Q3: 30.7 to 49.6). There was a significant negative correlation between dyspnea and PCS (r=-0.660, P<0.0001) and between dyspnea and MCS (r=-0.342, P<0.0411) (Fig. 1 and 2). The Zung
Depression Scale was available for 17 of these patients; their median score was 42.0 (Q1 to Q3: 33.0 to 46.0). There was a significant correlation between the Zung depression scale and PCS (r=
-0.578, P<0.0150) and between Zung depression scale and MCS
(r=-0.752, P<0.0005) (Fig. 3 and 4) indicating that in this cohort as perceived dyspnea increases patient self reported depression scores also increase. All data has been summarized (Table 2).

DISCUSSION
Health-related quality of life is defined as an individual’s
well-being as being affected over time by a disease, disability, or
disorder. The definition of HRQOL can be portrayed as many factors but it is, debilitating, disease specific symptoms that affect
patients view of HRQOL the most. Our retrospective study shows
the relationship between disease specific symptoms, in this case
dyspnea and its relationship with depression and HRQOL. Patient self reporting of dyspnea revealed that our cohort of PAH
patients on average get dyspneic on exertion with a MMRC score
of 1 which relates to “I get short of breath when hurrying on the
level or up a slight hill”. This explanation is somewhat expected
as these patients suffer from a purely vascular disease while lung
parenchyma stays intact. The pathogenesis of pulmonary hyper262
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tension is multifactorial and is characterized by abnormalities initiating in the small arteries of the pulmonary vasculature, including enhanced cell proliferation and reduced apoptosis, endothelial
dysfunction, thrombosis in situ, inflammation, and plexiform arteriopathy, leading to vascular remodeling and excessive vasoconstriction (McLaughlin et al., 2009). In the setting of PAH these
changes cause resistance for the blood flowing through the pulmonary arteries leading to increased pulmonary artery pressures
and increased pulmonary vascular resistance pressures eventually
leading to right heart failure due to increased after load, decreased
contractility, and reduced cardiac output (Waxman, 2012). This
combination of reduced cardiac output and increased pulmonary
vascular resistance creates a situation where exertion causes dyspnea and negatively affects HRQOL.
HRQOL is a measure of overall well being and it is affected by
both mental and physical components (Ware, 2000). It has been
reported before that when dyspnea is one of the presenting factors
in such conditions such as congestive heart failure it results in
mental and cognitive dysfunction (Pressler et al., 2010) for which
mechanisms are still unknown. The use of the SF-36 health survey
has been validated and demonstrated diminished HRQOL in other pulmonary disease as well such as COPD and IPF (Mahler and
Mackowiak, 1995; Martinez et al., 2000) where dyspnea is the
primary symptom. Quantitative measurement of HRQOL is heavily dependent on patient reported questionnaires and in the field
of PAH the use of the SF-36 questionnaire is limited to a few
studies (Chua et al., 2006; Taichman et al., 2005; Zlupko et al.,
2008). More recently in a subgroup of patients PAH due to congenital heart disease it was found that a decrease in physical aspects of HRQOL may be a determinant of mortality (Blok et al.,
2015).
The SF-36 Health Survey is a 36 question assessment tool
which yields an eight scale profile scores as well as a composite
http://dx.doi.org/10.12965/jer.150230
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physical health summary (PCS) and mental health summary
(MSC) (Ware, 2000). Of great interest in our study is that patients
with pulmonary arterial hypertension suffer from a slightly diminished mental and physical quality of life score as studied by
the SF-36. The median mental component score (MCS) in WHO
Group I PAH patient was 52.1 (Q1 to Q3:41.76 to 57.1; mean:
49.0 ± 11.7) and physical component scores (PCS) was 37.9 (Q1
to Q3:30.7 to 49.6; mean: 39.5 ± 11.0). Though the MCS score
was lightly diminished from the defined normal mean (Ware,
2000), PCS scores were markedly decreased. This may be in due
in part to the fact that these patients face dyspnea on exertion or
furthermore the trepidation that comes with physical activity in
this specific population. We further evaluated the effect of dyspnea on health related quality of life. It was found that as self reported patient dyspnea, according to the MMRC Dyspnea Scale
Score, increased, MCS decrease. There was a significant negative
correlation between the MMRC Dyspnea Scale Score and MCS
(r=-0.342, P<0.0411) and between dyspnea and PCS scores (r=0.660, P<0.0001). Taichman et al., have reported that worsening
function correlates with a reduced health related quality of life
(Taichman et al., 2005). Our study demonstrated that patient self
reported dyspnea also negatively correlates with a reduced mental
and physical quality of life. This is an important finding as patient
reported outcomes are more insightful in to how the patient feels
rather than quantitative measurements obtained in overall disease
severity assessment. This is especially important in a disease such
as PAH where disease severity does not always correlate with static values such as mean pulmonary arterial pressure or pulmonary
vascular resistance (Cenedese et al., 2006).
In addition our study demonstrated a significant negative correlation between patient self reported depression as measured by
the Zung Depression Scale and physical and mental component
score of the SF-36 questionnaire [Zung depression scale and PCS
(r=-0.578, P<0.0150, n=17) and between Zung depression
scale and MCS (r=-0.752, P<0.0005, n=17)]. To the best of our
knowledge this is the first study of its kind that shows the impact
that depression has on mental and physical health scores in the cohort of PAH patients.It is known that patients with PAH suffer
from depression and anxiety (Löwe et al., 2004). Our study highlights the relationship between depression and its possible effects
on the physical and mental components of HRQOL.
In general our study also highlights the importance of patient
reported outcomes (PROs). Dyspnea, depression and HRQOL are
often assessed with the use of questionnaires filled out by patients
and their treatment is based on patient centered care. Medical rehttp://dx.doi.org/10.12965/jer.150230

search has traditionally focused on concrete, often quantitative
biomedical outcomes rather than the qualitative,patient-centered
outcomes such as fatigue, health related quality of life, and patient
satisfaction (Laine and Davidoff, 1996). As our heath care system
progresses to a more multidisciplinary approach greater attention
needs to be placed on these PROs. PROs offer the advantage advantages by allowing healthcare providers to determine how the
disease is affecting the patient in the inside and possible effects of
treatment that may only be evident only to the patient. PROs are
able to be quickly administered and provide and additional dimension to diagnosing and managing a disease such as PAH. Although the Agency of Healthcare Research and Quality has made
strong strides in the area of patient-centered research, the birth of
the Patient-Centered Outcomes Research Institute propels us toward realizing the elusive goals of true patient centered care (Selby
et al., 2012). Patient-centered outcomes research that focuses on
HRQOL and its components can further enhance quality of care.
Though vasodialtory pharmaceutical options for WHO Group
I PAH exist such as phosphodiesterase 5 (PDE-5) inhibitors, endothelin receptor antagonists (ERAs) or prostacyclin derivatives
(Galiè et al., 2013), they focus more on hemodynamics and exercise tolerance. However there is evidence that non-pharmacological therapies such as pulmonary rehabilitation may address the
debilitating symptoms of chronic lung disease such as PAH (Talwar et al., 2014).
It has been suggested by ATS guidelines that exercise and pulmonary rehabilitation may further address the qualitative aspects
of this disease (Galiè et al., 2013; Sahni et al., 2015). This study
opens up the argument that, as clinicians we should also be focusing efforts on addressing the psychosomatic aspects of this debilitating disease and how to manage these damaging symptoms. As
pulmonary rehabilitation has been studied in this patient population with beneficial results (Sahni et al., 2015) it should be a adjunct therapy. Pulmonary rehabilitation has shown to decrease fatigue (Talwar et al., 2014), dyspnea (Reardon et al., 1994) and depression (Paz-Diaz et al., 2007). Furthermore pulmonary rehabilitation has been shown to increase health related quality of life
(Grunig et al., 2012) and exercise tolerance in the form of Six
Minute Walk Test (6MWT) (Chan et al., 2013).
Our study showed that patients with a chronic debilitating disease such as PAH are mentally and physically affected by their
symptoms, in particular dyspnea.In addition it is important that
underlying depression in PAH patient may be negatively affecting their HRQOL, which should be addressed.This is important
as treatment guidelines should consider quality of life as possible
http://www.e-jer.org
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therapeutic endpoint. Some of the limitations of this study are
that it is retrospective in nature and a small sample size due to the
rarity of this disease.In addition not all patients completely finished requested PROs which rendered the data unusable for analysis.
Patients with PAH suffer from diminished HRQOL which
correlates with their self reported perceived dyspnea. In addition
in PAH patients, as their self report depression score increased the
more their mental and physical health related quality of life scores
were affected. Healthcare providers need to appreciate the psychosocial impairment of patients with pulmonary hypertension. Pulmonary rehabilitation and cognitive behavioral interventions may
benefit these patients. Further studies are necessary to evaluate
and design interventions to improve HRQOL in these patients.
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